Epilepsy: key endpoint results by drug
The key endpoints of Epilepsy trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Epilepsy page.
Seizure frequency, % change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Brivaracetam | -53.0% | -24.4% | −28.7 | 50 mg/day · wk 7 · n 52 | NCT00175825 Phase 2, secondary |
| Cannabidiol (Epidiolex) | -41.2% | -13.7% | −27.5 | 20 mg/kg/day · wk 14.14 · n 86 | NCT02224690 Phase 3, secondary |
| Cenobamate | -71.9% | -39.6% | −32.3 | wk 22 · n 85 | NCT03678753 Phase 3, primary |
| Ganaxolone | -7.5% | 13.6% | −21.1 | wk 4 · n 64 | NCT05323734 Phase 3, primary |
| Lamotrigine | 75.4% | 32.1% | +43.3 | wk 19 · n 69 | NCT00104416 Phase 3, primary |
| Perampanel | -34.5% | -20.9% | −13.5 | 12 mg · wk 19 · n 133 | NCT00699972 Phase 3, primary |
| Zonisamide (Zonegran) | -48.4% | -26.6% | −21.8 | 100 mg · wk 16 · n 111 | NCT00327717 Phase 3, primary |
Drugs checked with no result here: 28 not reported, 15 not posted, 15 trial running.
50% responder rate
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Brivaracetam | 36% | 20% | +16 | 100 mg/day · wk 12 · n 100 | NCT00490035 Phase 3, secondary |
| Cenobamate | 57.8% | 21.7% | +36.1 | 200 mg/Day · wk 18 · n 109 | NCT01866111 Phase 2, secondary |
| Eslicarbazepine acetate | 30.6% | 31% | −0.4 | n 134 | NCT00988156 Phase 3, primary |
| Ganaxolone | 18.8% | 12.3% | +6.5 | wk 16 · n 64 | NCT05323734 Phase 3, secondary |
| natalizumab | 31.3% | 17.6% | +13.7 | 300 mg · wk 24 · n 32 | NCT03283371 Phase 2, secondary |
| Oxcarbazepine (Oxtellar XR) | 50% | 34% | +16 | 2400 mg/day · wk 16 · n 109 | NCT00772603 Phase 3, secondary |
| Pregabalin | 40.6% | 22.6% | +18 | 10 mg/kg/Day or 14 mg/kg/Day · wk 12 · n 97 | NCT01389596 Phase 3, secondary |
| Zonisamide (Zonegran) | 48.6% | 34.9% | +13.7 | 100 mg · wk 16 · n 111 | NCT00327717 Phase 3, secondary |
Drugs checked with no result here: 15 not posted, 27 not reported, 15 trial running.
Seizure freedom
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Brivaracetam | 86.7% | 73.3% (Lorazepam (LZP)) | — | 100 mg · n 15 | NCT03021018 Phase 2, secondary |
| Ganaxolone | 0% | 2.2% | −2.2 | wk 10 · n 95 | NCT00465517 Phase 2, secondary |
| Midazolam (Nayzilam) | 54.8% | 38.7% | +16.1 | wk 0.04 · n 31 | NCT01999777 Phase 3, primary |
| natalizumab | 0% | 2.9% | −2.9 | 300 mg · wk 24 · n 31 | NCT03283371 Phase 2, secondary |
| Perampanel | 14.3% | 50% (Standard of Care) | — | wk 52 · n 7 | NCT04497142 Phase 1/2, secondary |
| Zonisamide (Zonegran) | 1.8% | 2.8% | −1 | 100 mg · wk 16 · n 111 | NCT00327717 Phase 3, secondary |
Drugs checked with no result here: 18 not posted, 26 not reported, 15 trial running.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 65 approved or late-stage drugs with a featured trial in Epilepsy were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.